Accelerate Next Generation TCR Engineering, Enhance Target Identification, & Improve Solid Tumor Persistence to Transform
Clinical & Scalable Development for Patients in Need

April 23-25, 2024 | Boston MA

Join the 5th TCR-based Therapies for Solid Tumors Summit

In the face of challenging times for TCR-T therapy development, our conference serves as a crucial forum for researchers, clinicians, and industry leaders. Through dialogue, knowledge-sharing, and collaboration, we aim to provide essential support and drive progress in the field, helping to navigate through difficulties and advance towards groundbreaking therapies.

The recent submission of a Biologics License Application (BLA) by Adaptimmune is a remarkable milestone, signifying remarkable progress in gaining regulatory approval for their TCR-based cancer therapy. This achievement indicates a pivotal step forward, paving the way for broader accessibility of this innovative treatment to patients in critical need.

The 5th TCR-based Therapies for Solid Tumors Summit returns as your only TCR conference where TCR pipelines have the centre stage, serving as your ultimate platform to network with the most senior industry leaders in biopharma dedicated to accelerating clinical and commercial development of TCR-based therapeutics.

Industry News Banner
Industry News Banner
Industry News Banner

The World-Class Speaker Faculty Includes:

What Your Peers Have to Say:

''The 5th TCR-based Therapies for Solid Tumors Summit is the premiere event for researchers investigating TCR-based therapies. I look forward to great presentations and stimulating discussions with my colleagues'' – Regeneron Pharmaceuticals - 2024 Speaker